Page last updated: 2024-09-03

fosamprenavir and ritonavir

fosamprenavir has been researched along with ritonavir in 78 studies

Compound Research Comparison

Studies (fosamprenavir)	Trials (fosamprenavir)	Recent Studies (post-2010) (fosamprenavir)	Studies (ritonavir)	Trials (ritonavir)	Recent Studies (post-2010) (ritonavir)
174	55	37	5,419	1,291	2,772

Protein Interaction Comparison

Protein	Taxonomy	ritonavir (IC50)
Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)	6.1
Bile salt export pump	Homo sapiens (human)	2.085
ATP-dependent translocase ABCB1	Homo sapiens (human)	2.65
Cytochrome P450 3A4	Homo sapiens (human)	0.1623
Cytochrome P450 2D6	Homo sapiens (human)	2.3
Cytochrome P450 2C9	Homo sapiens (human)	2.458
Gag-Pol polyprotein	Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)	0.067
Substance-K receptor	Homo sapiens (human)	2.622
UDP-glucuronosyltransferase 1A1	Homo sapiens (human)	2.35
Thromboxane-A synthase	Homo sapiens (human)	0.076
Multidrug and toxin extrusion protein 2	Homo sapiens (human)	4.4
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	2.1933
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	4.4
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	2
Protease	Human immunodeficiency virus 1	4.9253

Research

Studies (78)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	53 (67.95)	29.6817
2010's	25 (32.05)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Chaudry, NI; Eron, JJ; Fiscus, SA; Kashuba, AD; Naderer, OJ; Pereira, AS; Wire, MB	1
Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB	1
Elston, RC; MacManus, S; Richards, N; Snowden, W; White, S; Yates, PJ	1
DeGoey, DA; Randolph, JT	1
Bellos, NC; DeJesus, E; Garris, C; Gathe, JC; Gladysz, A; Ive, P; Schürmann, D; Wood, R; Yeo, J	1
Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Higgs, C; Hill, A; Moyle, G; Nelson, M; Pozniak, A	1
Acosta, EP; Collier, AC; Downey, GF; Eshleman, SH; Kashuba, AD; Klingman, K; Mellors, JW; Scott, TR; Tierney, C; Vergis, EN	1
Arvieux, C; Tribut, O	1
Adamkiewicz, B; Lou, Y; Min, SS; Shelton, MJ; Wire, MB	1
Baker, KL; Berrey, MM; Jones, LS; Lou, Y; Shelton, MJ; Thomas, GJ; Wire, MB	1
Borland, J; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Wire, MB; Xue, ZG; Yuen, G	1
DeJesus, E; Elston, R; Garris, C; Gathe, JC; Givens, N; Gladysz, A; Sanne, I; Schürmann, D; Wood, R; Yeo, J	1
Corbett, AH; Eron, JJ; Kalvass, LA; Kashuba, AD; Lim, ML; Ngo, LT; Patterson, KB; Tien, HC	1
DeJesus, E; Eron, J; Estrada, V; Gathe, J; Katlama, C; Lackey, P; Patel, L; Shaefer, M; Staszewski, S; Sutherland-Phillips, D; Vavro, C; Wannamaker, P; Yau, L; Yeni, P; Yeo, J; Young, B	1
DeJesus, E; Lou, Y; Masterman, A; Min, SS; Piliero, PJ; Shelton, MJ; Stein, DS; Summers, K; Wire, MB	1
Lancaster, CT; Lou, Y; Luber, AD; Pappa, KA; Ruane, PJ; Shelton, MJ; Wire, MB	1
Sax, PE	2
Boucher, S; Breilh, D; Coureau, G; Dabis, F; Fleury, H; Lacoste, D; Lazaro, E; Merel, P; Neau, D; Pellegrin, I; Pellegrin, JL; Saux, MC; Thiébaut, R	1
Ballow, CH; Borland, J; Lewis, EW; Lin, J; Lou, Y; Shelton, MJ; Wire, MB; Yuen, G	1
Banik, N; Breske, A; Kruse, G; Kurowski, M; Mazur, D; Richter, H; Stocker, H; Walli, RK	1
Acosta, EP; Jennings, HC; Parks, DA; Taylor, CW	1
Arduino, RC; Torres, HA	1
Castagna, A; De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Gianotti, N; Lazzarin, A; Schira, G; Seminari, E; Soldarini, A; Uberti-Foppa, C	1
Bacarelli, A; Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Gatti, G; Pinnetti, C; Prosperi, M	1
Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R	1
Blenke, AA; Burger, DM; Koopmans, PP; Pharo, C; Rongen, GA; van der Lee, MJ; Verwey-van Wissen, CP	1
Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C	1
Borland, J; Chen, YC; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Yuen, GJ	1
Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y	1
Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F	1
Delgado, O; Murillas, J; Riera, M; Ventayol, P	1
Antoun, Z; Assoumou, KL; Bocket, L; Brun-Vézinet, F; Charpentier, C; Costagliola, D; Cottalorda, J; Descamps, D; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Peytavin, G; Ruffault, A; Tamalet, C	1
Bain, AM; Bedimo, RG; Busti, AJ; Hall, RG; Leff, RD; Meek, C; Mehvar, R	1
Bigelow, GE; Cao, YJ; Causon, RC; Fuchs, EJ; Hendrix, CW; Lancaster, CT; Lou, Y; Martinez, E; McCabe, S; Radebaugh, C; Smith, PF; Wire, MB	1
Calza, L; Chiodo, F; Manfredi, R; Pocaterra, D	1
Ait-Khaled, M; Antoun, Z; Calvez, V; Flandre, P; Katlama, C; Marcelin, AG; Molina, JM; Raffi, F; Yeni, P	1
Burty, C; Christian, B; Ghomari, K; May, T; Pavel, S; Pouaha, J; Rabaud, C; Vermersch, A; Yazdanpanah, Y	1
Abbasi, NR; Wang, N	1
Luque, I; Mallolas, J; Pérez-Elias, MJ; Rodríguez-Alcántara, F; Sánchez-Conde, M; Soriano, V	1
DeJesus, E; Hicks, CB; Lancaster, CT; Liao, Q; Pakes, GE; Pappa, KA; Ross, LL; Sension, MG; Sloan, LM; Wohl, DA	1
Aboulker, JP; Bentata, M; Brun-Vézinet, F; Capitant, C; Chazallon, C; Descamps, D; Katlama, C; Landman, R; Peytavin, G; Pialoux, G; Yéni, P	1
Ait-Khaled, M; Barbosa, I; Baril, JG; Cauda, R; Craig, C; Givens, N; Lou, Y; Molina, JM; Nichols, WG; Penco, G; Pialoux, G; Rinaldi, R; Soriano, V; Wire, MB; Yeo, J	1
Anderson, PL; Clay, PG; Glaros, AG; McRae, M	1
Clotet, B; Felizarta, F; Gutiérrez, F; Hernández-Quero, J; Lou, Y; Morellon, ML; Nichols, G; Ortega, E; Pérez-Elías, MJ; Pineda, JA; Rodríguez-Torres, M; Wire, MB	1
Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD	1
Babiker, A; Fox, L; Gey, D; Lopardo, G; Markowitz, N; Paton, N; Tavel, JA; Wentworth, D; Wyman, N	1
DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG	1
Corsini, F; Grosso, C; Lanzafame, M; Lattuada, E; Soldani, F; Storato, S; Vento, S	1
Boccara, F; Costagliola, D; Cotte, L; Gilquin, J; Lang, S; Mary-Krause, M; Partisani, M; Simon, A	1
Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF	1
Burleson, D; Gayton, JC; Laughlin, RT; Polenakovik, H	1
Delgado-Fernández, M; García-Figueras, C; López-Cortés, LF; Macías, J; Márquez-Solero, M; Martínez-Pérez, MA; Mata, R; Merchante, N; Merino, D; Omar, M; Pasquau, J; Pineda, JA; Ríos-Villegas, MJ; Rivero, A	1
Domingo, P; Gutierrez, M; Niubó, J; Podzamczer, D; Saumoy, M; Tiraboschi, J; Vila, A	1
Alvanzo, AA; Gruber, VA; Ma, Q; McCance-Katz, EF; Moody, DE; Morse, GD; Pade, PA; Prathikanti, S; Rainey, PM	1
Arribas, JR; Estébanez, M	1
Blick, G; Dupree, D; Garton, T; Greiger-Zanlungo, P; Gretz, S; Han, J; Pakes, GE; Wine, BC; Yau, LH	1
Adorni, F; Galli, M; Giacomet, V; Mameli, C; Rusconi, S; Viganò, A; Viganò, O; Zuccotti, GV	1
Aberg, JA; Castor, D; Cespedes, MS; Ford, SL; Lee, D; Lou, Y; Pakes, GE	1
Di Nicola, M; Falasca, K; Pizzigallo, E; Ucciferri, C; Vecchiet, J; Vignale, F	1
Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D	1
DeJesus, E; Edelstein, H; Felizarta, F; Ha, B; Hao, R; Huhn, G; Kumar, P; Pappa, K; Ross, L; Sloan, L; Small, CB; Stancil, B	1
Cassim, H; Cheng, K; Cotton, M; Ford, SL; Garges, HP; Givens, N; Lou, Y; Pavía-Ruz, N; Perger, T; Ross, LL; Sievers, J; Wire, MB	1
Cheng, K; Cotton, M; Duiculescu, D; Ford, SL; Fortuny, C; Garges, HP; Givens, N; Lou, Y; Perger, T; Ross, LL; Sievers, J; Tamarirt, DP; Wire, MB	1
Fang, A; Heera, J; Mendes da Costa, L; Plotka, A; Vourvahis, M	1
Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK	1
Burger, DM; Colbers, AP; Jacobs, BS; Schouwenberg, BJ; Velthoven-Graafland, K	1
Borland, J; Chen, S; Peppercorn, A; Piscitelli, SC; Song, I; Wajima, T	1
Barbour, AM; Gibiansky, L; Wire, MB	1
Cerini, C; Cozzi-Lepri, A; d'Arminio Monforte, A; Giralda, M; Nasta, P; Pimenta, JM; Salmon, D; Winnock, M	1

Reviews

7 review(s) available for fosamprenavir and ritonavir

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Peptidomimetic inhibitors of HIV protease. Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane	2004
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs, 2005, Volume: 65, Issue:5 Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides	2005
Fosamprenavir calcium plus ritonavir for HIV infection. Expert review of anti-infective therapy, 2007, Volume: 5, Issue:3 Topics: Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Organophosphates; Ritonavir; Sulfonamides	2007
Quality control of protease inhibitors. Journal of pharmaceutical sciences, 2008, Volume: 97, Issue:6 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides	2008
Protease inhibitor monotherapy: what is its role? Current HIV/AIDS reports, 2012, Volume: 9, Issue:2 Topics: Adipose Tissue; Bone Density; Carbamates; Drug Combinations; Drug Resistance, Viral; Furans; HIV Infections; Humans; Lopinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides	2012
Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4 Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Antifungal Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Echinocandins; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Mycoses; Organophosphates; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Voriconazole	2014

Trials

41 trial(s) available for fosamprenavir and ritonavir

Article	Year
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS (London, England), 2004, Apr-09, Volume: 18, Issue:6 Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Carbamates; Cholesterol; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Furans; Humans; Linear Models; Male; Middle Aged; Organophosphates; Oxazines; Prodrugs; Ritonavir; Sulfonamides; Triglycerides	2004
GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS (London, England), 2004, Mar-05, Volume: 18, Issue:4 Topics: Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Follow-Up Studies; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Organophosphates; Phenotype; Ritonavir; Sulfonamides	2004
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS (London, England), 2004, Jul-23, Volume: 18, Issue:11 Topics: Adolescent; Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Organophosphates; Patient Compliance; Ritonavir; Sulfonamides	2004
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS (London, England), 2005, Jan-28, Volume: 19, Issue:2 Topics: Adult; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides; Treatment Outcome	2005
Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:3 Topics: Adolescent; Adult; Carbamates; Clinical Trials as Topic; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides	2006
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:4 Topics: Adult; Area Under Curve; Carbamates; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides	2006
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clinical therapeutics, 2006, Volume: 28, Issue:5 Topics: Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Time	2006
Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:8 Topics: Adolescent; Adult; Area Under Curve; Carbamates; Clinical Trials as Topic; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Lopinavir; Male; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides	2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet (London, England), 2006, Aug-05, Volume: 368, Issue:9534 Topics: Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides	2006
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:9 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides	2006
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides	2007
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8 Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome	2007
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10 Topics: Adenine; Anti-Retroviral Agents; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Organophosphates; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir	2007
Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:11 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Area Under Curve; Carbamates; Drug Interactions; Female; Furans; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Organophosphates; Paroxetine; Ritonavir; Sulfonamides	2007
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antiviral therapy, 2007, Volume: 12, Issue:6 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides	2007
Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:2 Topics: Adult; Antitubercular Agents; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Furans; Humans; Male; Middle Aged; Organophosphates; Rifabutin; Ritonavir; Sulfonamides	2008
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy, 2008, Volume: 28, Issue:1 Topics: Adult; Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furans; Half-Life; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides	2008
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:6 Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Carbamates; Drug Combinations; Drug Interactions; Female; Fluorobenzenes; Furans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oligopeptides; Organophosphates; Prospective Studies; Pyridines; Pyrimidines; Ritonavir; Rosuvastatin Calcium; Sulfonamides	2008
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy, 2008, Volume: 28, Issue:7 Topics: Adult; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Interactions; Female; Furans; Humans; Male; Methadone; Narcotics; Organophosphates; Prodrugs; Ritonavir; Stereoisomerism; Sulfonamides	2008
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection. International journal of STD & AIDS, 2008, Volume: 19, Issue:8 Topics: Adult; Anti-HIV Agents; Carbamates; Diarrhea; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease; HIV-1; Humans; Hypertriglyceridemia; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome	2008
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:12 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load	2008
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:1 Topics: Adult; Carbamates; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Fever; Furans; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypercholesterolemia; Hypertriglyceridemia; Male; Organophosphates; Ritonavir; RNA, Viral; Spain; Sulfonamides; Viral Load; Viremia	2009
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS research and human retroviruses, 2009, Volume: 25, Issue:4 Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult	2009
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:1 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparagine; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Quinolines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load	2009
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:2 Topics: Adult; Aged; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load	2009
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. Pharmacotherapy, 2009, Volume: 29, Issue:8 Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Prodrugs; Pyridines; Ritonavir; Sulfonamides	2009
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12 Topics: Adolescent; Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Young Adult	2009
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. HIV medicine, 2010, Volume: 11, Issue:3 Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult	2010
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PloS one, 2010, Feb-23, Volume: 5, Issue:2 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Furans; HIV Infections; Humans; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptides; Opportunistic Infections; Organophosphates; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome	2010
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. AIDS research and human retroviruses, 2010, Volume: 26, Issue:4 Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure	2010
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. Antiviral therapy, 2010, Volume: 15, Issue:8 Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir	2010
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. AIDS patient care and STDs, 2011, Volume: 25, Issue:7 Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Drug Therapy, Combination; Female; Furans; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides	2011
Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Feb-01, Volume: 54, Issue:3 Topics: Anti-HIV Agents; Area Under Curve; Buprenorphine; Carbamates; Darunavir; Drug Interactions; Female; Furans; Half-Life; History, 16th Century; History, 17th Century; Humans; Male; Naloxone; Narcotic Antagonists; Opiate Substitution Treatment; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides	2012
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5 Topics: Adult; Area Under Curve; Carbamates; Disease Transmission, Infectious; Female; Fetal Blood; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Organophosphates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Sulfonamides; Young Adult	2013
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC infectious diseases, 2013, Jun-07, Volume: 13 Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; C-Reactive Protein; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Furans; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Middle Aged; Organophosphates; Plasminogen; Prospective Studies; Ritonavir; Sulfonamides; Vascular Cell Adhesion Molecule-1; Young Adult	2013
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data. The Pediatric infectious disease journal, 2014, Volume: 33, Issue:1 Topics: Carbamates; Cohort Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2014
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children. The Pediatric infectious disease journal, 2014, Volume: 33, Issue:1 Topics: Adolescent; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Child; Child, Preschool; Female; Furans; HIV Infections; HIV-1; Humans; Male; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2014
Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:12 Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Cyclohexanes; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Furans; Humans; Male; Maraviroc; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Triazoles	2013
Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers. International journal of antimicrobial agents, 2014, Volume: 44, Issue:2 Topics: Adolescent; Adult; Anti-HIV Agents; Antipsychotic Agents; Benzodiazepines; Carbamates; Chromatography, Liquid; Cross-Over Studies; Drug Interactions; Female; Furans; Healthy Volunteers; Humans; Male; Middle Aged; Olanzapine; Organophosphates; Ritonavir; Serum; Spectrophotometry, Ultraviolet; Sulfonamides; Young Adult	2014
Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11 Topics: Adult; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Interactions; Female; Furans; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Organophosphates; Oxazines; Piperazines; Pyridones; Ritonavir; Sulfonamides	2014
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. Journal of clinical pharmacology, 2014, Volume: 54, Issue:2 Topics: Adolescent; Carbamates; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Models, Biological; Organophosphates; Prodrugs; Ritonavir; Sulfonamides	2014

Other Studies

30 other study(ies) available for fosamprenavir and ritonavir

Article	Year
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:10 Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir	2007
Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Sep-15, Volume: 35, Issue:6 Topics: Adult; Anti-HIV Agents; Carbamates; Chemistry, Pharmaceutical; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Organophosphates; Prodrugs; Ritonavir; Semen; Sulfonamides	2002
SOLO trial results released. AIDS patient care and STDs, 2003, Volume: 17, Issue:2 Topics: Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; Humans; Nelfinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides	2003
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r]. MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Organophosphates; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Time Factors; Viral Load	2003
[Potent new protease inhibitor. Boostered protease inhibitors--a separate class of drugs]. MMW Fortschritte der Medizin, 2003, Apr-28, Volume: 145 Spec No 1 Topics: Acquired Immunodeficiency Syndrome; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Organophosphates; Patient Compliance; Ritonavir; Sulfonamides; Treatment Outcome	2003
[FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners]. MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1 Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cross-Over Studies; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Prodrugs; Ritonavir; Saquinavir; Sulfonamides	2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. Journal of acquired immune deficiency syndromes (1999), 2004, Nov-01, Volume: 37, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Metabolic Clearance Rate; Middle Aged; Organophosphates; Ritonavir; RNA, Viral; Saquinavir; Sulfonamides; Viral Load	2004
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Carbamates; Diarrhea; Drug Administration Schedule; Drug Combinations; Esomeprazole; Female; Furans; Headache; Humans; Male; Middle Aged; Nausea; Organophosphates; Ritonavir; Sulfonamides	2006
Meeting report. Report from ICAAC. AIDS clinical care, 2006, Volume: 18, Issue:12 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Cyclopropanes; Furans; HIV Infections; Humans; Oligopeptides; Organic Chemicals; Organophosphates; Oxazines; Patient Compliance; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Viral Load	2006
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Antiretroviral Therapy, Highly Active; Carbamates; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV-1; Humans; Organophosphates; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2007
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10 Topics: Adenine; Adolescent; Adult; Antiviral Agents; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome	2007
[Two year use of Telzir: what are the perspectives?]. Medecine et maladies infectieuses, 2007, Volume: 37, Issue:3 Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organophosphates; Phenotype; Ritonavir; Sulfonamides	2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:4 Topics: Adult; Anti-HIV Agents; Area Under Curve; Attention; Bilirubin; Carbamates; Chromatography, High Pressure Liquid; Female; Furans; HIV Infections; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Plasma; Ritonavir; Sulfonamides; Time Factors	2007
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors. Scandinavian journal of infectious diseases, 2007, Volume: 39, Issue:9 Topics: Adult; Algorithms; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphates; Prevalence; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides	2007
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. Fundamental & clinical pharmacology, 2008, Volume: 22, Issue:1 Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides	2008
[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26, Issue:3 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides	2008
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:6 Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2008
Lower dose of ritonavir approved for use with fosamprenavir. AIDS clinical care, 2007, Volume: 19, Issue:12 Topics: Carbamates; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration	2007
Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection. Journal of acquired immune deficiency syndromes (1999), 2008, Nov-01, Volume: 49, Issue:3 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lamivudine; Male; Organophosphates; Prospective Studies; Ritonavir; Sulfonamides; Zidovudine	2008
[Individualized therapy with fosamprenavir/r. A PI suitable in liver problems]. MMW Fortschritte der Medizin, 2008, Apr-28, Volume: 150 Spec No 1 Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Furans; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Liver Function Tests; Organophosphates; Ritonavir; Sulfonamides; Viral Load	2008
Doxorubicin-induced hyperpigmentation. Dermatology online journal, 2008, Oct-15, Volume: 14, Issue:10 Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carbamates; Doxorubicin; Drug Combinations; Furans; Humans; Lamivudine; Lip Diseases; Male; Melanosis; Nails, Malformed; Organophosphates; Ritonavir; Sarcoma, Kaposi; Sulfonamides; Tongue Diseases; Zidovudine	2008
Optimal fosamprenavir regimen to prevent lipid abnormalities. Acta bio-medica : Atenei Parmensis, 2009, Volume: 80, Issue:3 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Hyperlipidemias; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Triglycerides	2009
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Archives of internal medicine, 2010, Jul-26, Volume: 170, Issue:14 Topics: Adult; Anti-HIV Agents; Carbamates; Case-Control Studies; Cohort Studies; Confidence Intervals; Dideoxynucleosides; Female; France; Furans; HIV Infections; Hospitals, Isolation; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Organophosphates; Regression Analysis; Risk; Ritonavir; Sulfonamides	2010
Avascular necrosis of the talus in a HIV-infected patient. Foot & ankle international, 2010, Volume: 31, Issue:12 Topics: Adenine; Carbamates; Deoxycytidine; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphates; Organophosphonates; Orthotic Devices; Osteonecrosis; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Talus; Tenofovir	2010
Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV medicine, 2011, Volume: 12, Issue:7 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV-1; Humans; Male; Organophosphates; Pilot Projects; Prospective Studies; Ritonavir; RNA, Viral; Spectrum Analysis; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication	2011
Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study. International journal of STD & AIDS, 2012, Volume: 23, Issue:3 Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; Humans; Lipids; Male; Middle Aged; Organophosphates; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load	2012
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. BMC infectious diseases, 2012, Aug-06, Volume: 12 Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Child; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Oligopeptides; Organophosphates; Pyridines; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load	2012
Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. Journal of medical virology, 2013, Volume: 85, Issue:5 Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Carbamates; CD4 Lymphocyte Count; Darunavir; Dyslipidemias; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolome; Middle Aged; Organophosphates; Prospective Studies; Protease Inhibitors; Ritonavir; Sulfonamides; White People	2013
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients. European journal of internal medicine, 2013, Volume: 24, Issue:6 Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine	2013
Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study. HIV clinical trials, 2016, Volume: 17, Issue:3 Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cause of Death; CD4 Lymphocyte Count; Coinfection; Female; Furans; Hepatitis; HIV Infections; Humans; Liver Function Tests; Male; Middle Aged; Mortality; Organophosphates; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load	2016